Rigel Pharmaceuticals Inc RIGL
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover RIGL, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Rigel Announces Reverse Stock Split
-
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
-
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
-
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
-
Rigel to Present at the Jefferies Global Healthcare Conference
-
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
-
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $10.90
- Day Range
- $10.65–11.24
- 52-Week Range
- $7.12–17.30
- Bid/Ask
- $10.75 / $12.00
- Market Cap
- $188.75 Mil
- Volume/Avg
- 59,572 / 183,804
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 147
- Website
- https://www.rigel.com
Comparables
Valuation
|
Metric
|
RIGL
|
TGTX
|
ATXS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 20.55 | — |
Price/Book Value | — | 19.85 | 2.40 |
Price/Sales | 1.56 | 10.66 | — |
Price/Cash Flow | — | 37.30 | — |
Price/Earnings
RIGL
TGTX
ATXS
Financial Strength
|
Metric
|
RIGL
|
TGTX
|
ATXS
|
|---|---|---|---|
Quick Ratio | 1.05 | 2.76 | 33.41 |
Current Ratio | 1.26 | 3.62 | 33.83 |
Interest Coverage | −1.95 | 4.45 | — |
Quick Ratio
RIGL
TGTX
ATXS
Profitability
|
Metric
|
RIGL
|
TGTX
|
ATXS
|
|---|---|---|---|
Return on Assets (Normalized) | −7.25% | 27.97% | −23.38% |
Return on Equity (Normalized) | — | 73.42% | −40.10% |
Return on Invested Capital (Normalized) | −11.44% | 42.25% | −29.23% |
Return on Assets
RIGL
TGTX
ATXS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Bdqtytsj | Pctb | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vkysbcct | Qxqch | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cbfjkvzb | Xcblkn | $118.7 Bil | |||
| Moderna Inc
MRNA
| Gvwnnwhj | Thrn | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mrmsxlql | Knlzrr | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Llphvcw | Ndpy | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Nzkzyllf | Mgwn | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gjprgvcxp | Wjyrgq | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Scnlsby | Jthq | $15.0 Bil | |||
| Incyte Corp
INCY
| Mwqzjysrt | Hkpjnqp | $13.5 Bil |